Guidea Femovate - Dionysus Health is bringing a disruptive diagnostic tool, The Enlighten Test, to market, aiming to revolutionize women’s mental health through precision psychiatry. Launching as a Laboratory Developed Test (LDT) in 2025, the test addresses postpartum depression (PPD) prediction, with a long-term strategy to expand into adjacent markets like PMS, PMDD, and perimenopausal depression.

For more information about Nawara Health, visit dionysushealth.com and follow them on LinkedIn

For more information on Femovate visit www.femovate.com and follow us on LinkedIn

For interviews please contact Theresa Neil

Stay in touch

The application period for Femovate 2023-24 is now closed. Follow us on LinkedIn for updates and the selected startups announcement.